Pre-Clinical Models of Infectious Diseases
Updated
Solicitation from the National Institutes of Health. Due Dec 7, 2026, 3:00 PM (UTC-5), 48 days left.
| Solicitation number | 75N93027R00003 |
|---|---|
| Agency | National Institutes of Health |
| Office | National Institutes of Health Niaid |
| Notice type | Solicitation |
| Set-aside | None |
| Trade (NAICS) | Research and Development in Biotechnology (except Nanobiotechnology) (541714) |
| Product or service code | AN11 |
| Posted | Oct 19, 2026 |
| Response deadline | Dec 7, 2026, 3:00 PM (UTC-5) (48 days left) |
| Add the deadline to | Google Calendar · Apple / Outlook (.ics) |
Official notice and attachments
Description
Pre-solicitation Notice Information Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.
The NIAID, Division of Microbiology and Infectious Diseases has a requirement to provide and develop animal models in order to advance our understanding of infectious diseases as well as advance the development of therapeutics and vaccines for infectious diseases. Description The National Institute of Allergy and Infectious Diseases (NIAID) supports and facilitates research that focuses on understanding, treating and, ultimately, preventing infectious, immunologic, and allergenic diseases.
The NIAID Division of Microbiology and Infectious Diseases (DMID) supports and facilitates research to understand, control and prevent human disease caused by infectious agents. Basic, applied and translational research to develop and assess therapeutics, vaccines, and diagnostics is supported through research grants, cooperative agreements, and contracts. In turn, DMID further supports and facilitates research ongoing under these funding mechanisms and through other programs via an array of preclinical and clinical resources and services to support multiples stages of the product development pipeline.
These resources and services include genomic and gene sequencing services, provision of high quality biological materials, biocontainment facilities, and pre-clinical and clinical translational research resources (niaid.nih.gov/research/resources).
The current NIAID Preclinical Models of Infectious Diseases IDIQ contract program is one of DMID’s preclinical services resources and supports the development and refinement of animal models and animal replacement models of infectious diseases, models that subsequently are used to evaluate candidate medical countermeasures against these diseases. In addition, these contracts facilitate regulatory submissions, patents, and other intellectual property applications by extramural investigators who request evaluation of their products.
This program serves the DMID mission of supporting investigator-initiated research by providing critical data needed to apply for grant or other funding. Finally, these contracts enable product developers and sponsors to make key go/no-go decisions for candidate therapeutics, vaccines, and diagnostics. In addition to meeting the needs of extramural researchers, this program provides crucial data to our DHHS agency partners.
These data will facilitate the advancement of promising candidate medical countermeasures against priority biodefense and emerging infectious agents to approval or licensure, and, in some cases, eventual deposit in the Strategic National Stockpile. As background, in 2024, 40 institutions were awarded base contracts under the Preclinical Models of Infectious Diseases IDIQ contract program.
This program was a re-competition of her Animal Models of Infectious Diseases IDIQ contract program, and its overarching goal was to provide capability in a broad range of animal and animal replacement models for use in evaluating promising candidate countermeasures (vaccines, therapeutics, diagnostics) against the broad range of infectious agents that are in the purview of DMID.
The breadth of the existing contractor pool has enabled a rapid and effective response to emerging infectious diseases, such as COVID-19, and emergency preparedness priorities. Awarded contracts were divided into 4 model-specific pools: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents The Preclinical Models of Infectious Diseases program will continue to provide the capability and capacity to develop and employ animal and animal replacement models (e.g., organ-on-a-chip technology) of infectious diseases for screening and product evaluation and addresses a critical stage in this pipeline by bridging in vitro testing and eventual clinical evaluation, including as needed, studies conducted under the guidance of 21 CFR 58, “Good Laboratory Practices”.
In addition, for candidate products that are unable to be assessed for clinical efficacy in phase II or III trials for ethical or practical reasons, contracts awarded under this solicitation will enable regulatory approval or licensure via the guidance of the FDA’s Animal Efficacy Rule (21 CFR 314.610 and 601.91). This anticipated “ramp-on” solicitation will award multiple IDIQ base contracts to successful offerors that propose a general approach to the requirements, allowing them to join the existing contractor pools.
Successful offerors will qualify for the pool and be eligible to compete for future task order awards in the existing model-specific Task Areas: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents Offerors are encouraged to consider submission of proposals to one or more of the above Task Areas (depending upon capabilities).
Contract awards are anticipated to the organizations whose proposals offer the best value to the Government. For the purposes of this solicitation, the following definitions apply: Animal replacement tissue technologies derived from human or animal tissue (in particular lung, liver, immune system, brain, skin/soft tissue or gastrointestinal tissues): Organoids Organs on chi
The description continues in the official notice.
Contracting contact
- Ignacio Reyes, Contracting Officer · [email protected] · (301) 435-7574
- Hassanzadeh Makou, Hamed · [email protected] · (301) 761-7466
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
Is your business small enough?
For NAICS 541714, a business counts as small if it has no more than 1,000 employees (SBA size standard, with exceptions in the notes). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.
Companies that win this kind of work
Federal contractors paid for research and development in biotechnology work, who also hold NIH contracts (last 12 months): possible competitors, or partners to team with.
- PPD Development LP $40.1 million in this trade
- Battelle Memorial Institute $27.0 million in this trade
- Technical Resources International, Inc. $22.3 million in this trade
- Psychogenics Inc. $14.8 million in this trade
- Trustees Of Boston University $10.9 million in this trade
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.
Research and Development in Biotechnology contracts right now
There are 38 open government contract opportunities in this trade (NAICS 541714), 7 posted in the last 7 days; 47% are set aside for small businesses. The agencies buying the most are National Institutes of Health, Office of Assistant Secretary for Preparedness and Response and Defense Advanced Research Projects Agency (DARPA). Most of the work with a stated place is in District of Columbia, New Mexico and Maryland. A notice in this trade gives a median of 72 days from posting to deadline; this one gives 49 days.
All open research and development in biotechnology contracts
Coming up in this trade
Planned contracts from the agencies' procurement forecasts, often months before a solicitation. Plans can change.
Recent awards in this trade
- Red Duke Strategies LLC $1.5 million · Department of Veterans Affairs · Sep 23, 2026
- Reagan-Udall Foundation For The Food And Drug Administration, Inc. $1.2 million · Defense Advanced Research Projects Agency (DARPA) · Sep 14, 2026
From the award notices agencies publish.